Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma
Clinical trial NCT04979585 · UNKNOWN
Trial details
- NCT number
- NCT04979585
- Sponsor
- Di Wu
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-15
- Primary completion
- 2023-04-14
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.